IRIS
PARISI, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.219
AS - Asia 2.068
EU - Europa 1.161
SA - Sud America 464
AF - Africa 85
OC - Oceania 4
Totale 6.001
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.128
SG - Singapore 615
VN - Vietnam 497
CN - Cina 383
BR - Brasile 347
IT - Italia 343
RU - Federazione Russa 336
HK - Hong Kong 288
FR - Francia 126
DE - Germania 89
IN - India 65
GB - Regno Unito 54
BD - Bangladesh 52
FI - Finlandia 47
MX - Messico 41
AR - Argentina 38
NL - Olanda 36
IE - Irlanda 35
CA - Canada 34
IQ - Iraq 24
CI - Costa d'Avorio 22
AT - Austria 21
EC - Ecuador 21
ID - Indonesia 20
ZA - Sudafrica 20
CO - Colombia 17
SE - Svezia 16
PK - Pakistan 15
JP - Giappone 14
ES - Italia 13
VE - Venezuela 13
KR - Corea 12
PL - Polonia 10
SA - Arabia Saudita 10
MA - Marocco 9
TR - Turchia 9
CL - Cile 8
EG - Egitto 8
PH - Filippine 8
PY - Paraguay 8
AE - Emirati Arabi Uniti 7
PE - Perù 7
UA - Ucraina 7
KE - Kenya 6
LT - Lituania 6
TW - Taiwan 6
DZ - Algeria 5
TH - Thailandia 5
TN - Tunisia 5
UZ - Uzbekistan 5
AU - Australia 4
BG - Bulgaria 4
CR - Costa Rica 4
IL - Israele 4
KZ - Kazakistan 4
LB - Libano 4
PA - Panama 4
AZ - Azerbaigian 3
BY - Bielorussia 3
JO - Giordania 3
NG - Nigeria 3
NP - Nepal 3
PR - Porto Rico 3
UY - Uruguay 3
AL - Albania 2
BO - Bolivia 2
JM - Giamaica 2
QA - Qatar 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BH - Bahrain 1
CH - Svizzera 1
CY - Cipro 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IR - Iran 1
KG - Kirghizistan 1
KW - Kuwait 1
LY - Libia 1
MM - Myanmar 1
MU - Mauritius 1
MY - Malesia 1
MZ - Mozambico 1
OM - Oman 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
ZW - Zimbabwe 1
Totale 6.001
Salva come PNG Salva come JPEG
Città #
Ashburn 728
San Jose 346
Singapore 345
Hong Kong 280
Ho Chi Minh City 175
Dallas 168
Hanoi 109
Beijing 99
Boardman 89
Lauterbourg 71
The Dalles 66
Los Angeles 62
Hefei 61
Council Bluffs 54
Moscow 52
Munich 41
Helsinki 36
Milan 35
Orem 35
Dublin 33
New York 32
São Paulo 32
Santa Clara 26
Buffalo 25
Da Nang 24
Rome 24
Shenzhen 24
Mexico City 23
Abidjan 22
Chennai 21
Nuremberg 19
Ancona 18
Chandler 17
Chicago 17
Montreal 17
Fairfield 15
Haiphong 14
London 14
Seattle 12
Shanghai 12
Tokyo 12
Zhengzhou 12
Brasília 11
Camerino 11
Houston 11
Vienna 11
Amsterdam 10
Denver 10
Des Moines 10
Turku 10
Washington 10
Bologna 9
Hải Dương 9
Manchester 9
Miano 9
Warsaw 9
Can Tho 8
Frankfurt am Main 8
Jacksonville 8
New Delhi 8
Rio de Janeiro 8
Urbisaglia 8
Biên Hòa 7
Boston 7
Dhaka 7
Elk Grove Village 7
Florence 7
Johannesburg 7
Lima 7
Ninh Bình 7
Stockholm 7
Ann Arbor 6
Baghdad 6
Bari 6
Bogotá 6
Erbil 6
Guangzhou 6
Medellín 6
Phoenix 6
Quito 6
Secaucus 6
Thái Bình 6
Toronto 6
Asunción 5
Atlanta 5
Campinas 5
Cotia 5
Goiânia 5
Guayaquil 5
Lawrence 5
Miami 5
Mumbai 5
Nairobi 5
Naples 5
Porto Alegre 5
Princeton 5
Saint Louis 5
Salt Lake City 5
San Francisco 5
Seoul 5
Totale 3.724
Salva come PNG Salva come JPEG
Nome #
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 189
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 157
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 131
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status 124
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 118
Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report 115
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 108
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 106
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis 105
Pemigatinib in pazienti affetti da colangiocarcinoma localmente avanzato o metastatico con fusione o riarrangiamento di FGFR2 pretrattati: analisi congiunta degli studi di coorte multicentrici, osservazionali, "real-world" francese PEMI-BIL e italiano PEMI-REAL 105
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 103
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 102
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 101
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers 98
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 96
Communication in oncology between healthcare providers, patients, the scientific community, and the media: recommendations from the Italian Association of Medical Oncology (AIOM) 95
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 94
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 94
Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study 91
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 90
Immunotherapy in Triple-Negative Breast Cancer 90
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 88
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study 87
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 86
Changes in clinical presentation, management, and survival outcomes in patients affected by colorectal cancer following COVID-19 pandemic 85
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 85
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 83
Evaluation of prognostic factors for survival in transverse colon cancer 81
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies 80
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 79
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 79
What is known about theragnostic strategies in colorectal cancer 78
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 78
Multimodality treatment in metastatic gastric cancer: From past to next future 77
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study 77
The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer 76
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 75
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort 74
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study 74
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 74
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 73
Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen 73
How to best exploit immunotherapeutics in advanced gastric cancer: Between biomarkers and novel cell-based approaches 72
Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption 72
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 71
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 70
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 68
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab 68
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 68
Is it a new era for intrahepatic cholangiocarcinoma? 67
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 66
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 66
Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis 65
The emerging role of immunotherapy in the treatment of anal cancer 63
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 59
A case of segmental hepatic necrosis complicating oxaliplatin and capecitabine chemotherapy: A case report and review of the literature 57
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 57
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 57
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 56
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 55
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study 55
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 55
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 55
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 54
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 54
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 53
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 52
Looking for a place for dose-dense TMZ regimens in GBM patients: An experience with MGMT exploratory evaluation 52
Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study 50
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 48
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy 47
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome 47
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 47
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 45
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 45
SEX-RELATED DIFFERENCES IN EFFICACY AND SAFETY OF IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA: SYSTEMATIC REVIEW AND META-ANALYSIS OF LANDMARK PHASE III TRIALS AND VALIDATION IN ROUTINE CLINICAL PRACTICE 45
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 44
Where are we with treatment options after first line in small cell lung cancer?-Report of two opposite cases treated with CAPTEM regimen and possible perspectives 43
Into the storms: Organising oncological home care services during natural disasters and global pandemics 37
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 34
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 32
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 32
SHORT-COURSE RADIOTHERAPY FOR OLDER PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AND UNFIT FOR CHEMOTHERAPY: THE SOFT STUDY 30
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 15
Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors 10
Preliminary report on advanced biliary cancer patients receiving multimodality treatment in the immunotherapy era: a real-world multicentre experience 10
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study 7
The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study 7
Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab 3
Totale 6.239
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.158
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.158
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214 0 0 0 0 0 0 0 0 0 0 0 4
2021/202231 0 2 0 0 0 2 1 1 13 1 6 5
2022/202371 5 3 4 10 0 11 0 2 18 7 10 1
2023/2024254 16 3 13 19 18 27 2 13 1 71 25 46
2024/20251.356 151 76 42 12 39 50 200 67 274 96 115 234
2025/20264.484 213 343 198 478 337 303 849 436 469 494 248 116
Totale 6.239